Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 13/20 | 0.47 |
| ▸ | CCNE1 | P24864 | 12/20 | 0.47 |
| ▸ | CCNE2 | O96020 | 11/20 | 0.47 |
| ▸ | CDK4 | P11802 | 6/20 | 0.46 |
| ▸ | CDK1 | P06493 | 5/20 | 0.46 |
| ▸ | CCND1 | P24385 | 5/20 | 0.46 |
| ▸ | CCNB2 | O95067 | 4/20 | 0.46 |
| ▸ | CCNB1 | P14635 | 4/20 | 0.46 |
| ▸ | CCNB3 | Q8WWL7 | 4/20 | 0.46 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.44 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.44 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.44 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.44 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.44 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.44 |
| ▸ | CCND2 | P30279 | 1/20 | 0.43 |
| ▸ | CCND3 | P30281 | 1/20 | 0.43 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL179490 | 0.81 | CCNE1 (0.52) | CDK2CCNE1CCNE2CDK4CDK1 | |
| SCHEMBL20049878 | 0.81 | CCNE1 (0.43) | CDK2CCNE1CCNE2CDK4CDK1 | |
| SCHEMBL21389733 | 0.80 | CCNE1 (0.49) | CDK2CCNE1CCNE2CDK4CDK1 | |
| SCHEMBL21369612 | 0.75 | CCNE1 (0.45) | CDK2CCNE1CCNE2CDK4CDK1 | |
| SCHEMBL18135139 | 0.72 | CDK2 (0.64) | CDK2CCNE1CCNE2CDK4CDK1 | |
| SCHEMBL233711 | 0.71 | CDK2 (0.60) | CDK2CCNE1CCNE2CDK4CDK1 | |
| SCHEMBL21770026 | 0.71 | CDK2 (0.53) | CDK2CCNE1CCNE2CDK4CDK1 | |
| SCHEMBL20206550 | 0.71 | HCAR2 (0.33) | — | |
| SCHEMBL19261385 | 0.70 | CCND3 (0.43) | CDK2CCNE1CCNE2CDK4CDK1 | |
| SCHEMBL13543136 | 0.69 | SMN1; SMN2 (0.60) | CDK2CCNE1CCNE2CDK4CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230364097-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-20170360795-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. (US) | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170360795-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | PIK3CA, MCL1, PIK3CB | CDK2 85/4885CCNE1 621/4885CCNE2 1281/4885 |
| US-20230364097-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | PIK3CA, MCL1, PIK3CB | CDK2 85/4885CCNE1 621/4885CCNE2 1281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.